Lack of association between the interleukin-1 gene complex and schizophrenia in a Japanese population

Psychiatry and Clinical Neurosciences

Volumn 61, Issue 4, 2007, Pages 364-369

  Watanabe, Yuichiro ^a,b   Nunokawa, Ayako ^a   Kaneko, Naoshi ^a   Muratake, Tatsuyuki ^c   Koizumi, Masataka ^a   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c Furumachi Mental Clinic   (Japan)

Author keywords

Case control study; Interleukin 1; Schizophrenia; Single nucleotide polymorphism; Variable number of tandem repeat

Indexed keywords

INTERLEUKIN 1;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; SAMPLE SIZE; SCHIZOPHRENIA;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; INTERLEUKIN-1; JAPAN; LINKAGE DISEQUILIBRIUM; MALE; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SAMPLE SIZE; SCHIZOPHRENIA;

EID: 34347375400     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2007.01671.x     Document Type: Article

References (45)

1. Nawa H, Takahashi M, Patterson PH. Cytokine and growth factor involvement in schizophrenia - support for the developmental model. Mol. Psychiatry 2000 5 : 594 603.
2. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000 23 : 618 625.
3. Tohmi M, Tsuda N, Watanabe Y, Kakita A, Nawa H. Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. Neurosci. Res. 2004 50 : 67 75.
4. Tsuda N, Tohmi M, Mizuno M, Nawa H. Strain-dependent behavioral alterations induced by peripheral interleukin-1 challenge in neonatal mice. Behav. Brain Res. 2006 166 : 19 31.
5. Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 1998 24 : 285 301.
6. Suzuki E, Shintani F, Kanba S, Asai M, Nakaki T. Induction of interleukin-1β and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci. Lett. 1996 215 : 201 204.
7. Xu H-M, Wei J, Hemmings GP. Changes of plasma concentrations of inerleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia. Br. J. Psychiatry 1994 164 : 251 253.
8. McAllister CG, van Kammen DP, Rehn TJ et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry 1995 152 : 1291 1297.
9. Akiyama K. Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr. Res. 1999 37 : 97 106.
10. Moots RJ, Al-Saffar Z, Hutchinson D et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann. Rhuem. Dis. 1999 58 : 585 587.
11. Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia. Schizophr. Res. 2001 50 : 169 175.
12. Sirota P, Meiman M, Herschko R, Bessler H. Effects of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Pschiatry Res. 2005 134 : 151 159.
13. Katila H, Appelberg B, Hurme M, Rimón R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 1994 12 : 29 34.
14. Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1β and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J. Basic Clin. Physiol. Pharmacol. 1995 6 : 61 69.
15. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995 19 : 75 83.
16. Maes M, Bosmans E, Ranjan R et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 1996 21 : 39 50.
17. Song C, Lin A, Kenis G, Bosmans E, Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr. Res. 2000 42 : 157 164.
18. Toyooka K, Watanabe Y, Iritani S et al. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci. Res. 2003 46 : 299 307.
19. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry 1993 150 : 1408 1410.
20. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry 1995 38 : 297 302.
21. Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 1996 20 : 199 203.
22. Naudin J, Capo C, Giusano B, Mège JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophr. Res. 1997 26 : 227 233.
23. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr. Res. 1997 25 : 123 129.
24. Kim YK, Lee MS, Suh KY. Decreased interleukin-2 protein in Korean schizophrenic patients. Biol. Psychiatry 1998 43 : 701 704.
25. Erbaǧci AB, Herken H, Köylüoglu O, Yilmaz N, Tarakçioglu M. Serum IL-1β, sIL-2R, IL-6, IL-8 and TNF-α in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Med. Inflamm. 2001 10 : 109 115.
26. Pociot F, Mølvig J, Wogensen L, Worsaae H, Nerup J. A TaqI Polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur. J. Clin. Invest. 1992 22 : 396 402.
27. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin. Exp. Immunol. 1995 99 : 303 310.
28. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1β genes. Eur. J. Immunol. 1998 28 : 2598 2602.
29. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand. J. Immunol. 1998 47 : 195 198.
30. Hulkkonen J, Laippala P, Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1β plasma levels in healthy individuals. Eur. Cytokine Netw 2000 11 : 251 255.
31. Hacker UT, Erhardt S, Tschöp K, Jelinek T, Endes S. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1β after live yellow fever vaccination. Clin. Exp. Immunol. 2001 125 : 465 469.
32. Katila H, Hänninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol. Psychiatry 1999 4 : 179 181.
33. Zanardini R, Bocchio-Chiavetto L, Scassellati C et al. Association between IL-1β -511C/T and IL-1RA (86bp) n repeats polymorphisms and schizophrenia. J. Psychiatr. Res. 2003 37 : 457 462.
34. Kim SJ, Lee HJ, Koo HG et al. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatr. Genet 2004 14 : 165 167.
35. Papiol S, Rosa A, Gutiérrez B et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J. Med. Genet 2004 41 : 219 223.
36. Laurent C, Thibaut F, Ravassard P et al. Detection of two new polymorphic sites in the human interleukin-1β gene: lack of association with schizophrenia in a French population. Psychiatr. Genet 1997 7 : 103 105.
37. Tatsumi M, Sasaki T, Sakai T et al. Genes for interleukin-2 receptor β chain, interleukin-1β, and schizophrenia: no evidence for the association or linkage. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 1997 74 : 338 341.
38. Chowdari KV, Xu K, Zhang F et al. Immune related genetic polymorphisms and schizophrenia among the Chinese. Hum. Immunol. 2001 62 : 714 724.
39. Meisenzahl EM, Rujescu D, Kirner A et al. Association of an interleukin-1β genetic polymorphism with altered brain structure in patients with schizophrenia. Am. J. Psychiatry 2001 158 : 1316 1319.
40. Yang J, Si T, Ling Y et al. Association study between interleukin-1β gene (IL-1β) and schizophrenia. Life Sci. 2003 72 : 3017 3021.
41. Rosa A, Peralta V, Papiol S et al. Intereukin-1β (IL-1β) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. Am. J. Med. Genet. Part B 2004 124B : 10 14.
42. Saiz PA, Garcia-Portilla MP, Arango C et al. Interleukin-1 gene complex in schizophrenia: an association study. Am. J. Med. Genet. Part B 2006 141B : 678 680.
43. Hirakawa M, Tanaka T, Hashimoto Y, Kuroda M, Takagi T, Nakamura Y. JSNP: a database of common gene variations in the Japanese population. Nucleic Acids Res. 2002 30 : 158 162.
44. Watanabe Y, Fukui N, Muratake T et al. Association study of a functional promoter polymorphism of the X-box binding protein 1 gene in Japanese patients with schizophrenia. Psychiatry Clin. Neurosci. 2006 60 : 633 635.
45. Erdfelder E, Faul F, Buchner A. GPOWER: a general power analysis program. Behav. Res. Methods Instrum. Comput. 1996 28 : 1 11.